Company intelligence / Profile preview

Merz Biolab Farma

São Paulo, São Paulo, Brazil

Ownership: Private
Development stage: Other

Overview

Merz Biolab is a joint venture between the German pharmaceutical group Merz and the Brazilian pharmaceutical company Biolab Farmacêutica. Established to strengthen the presence of Merz's portfolio in the Brazilian market, the company focuses on medical aesthetics, neurosciences, and dermatology. Its primary product offerings include Xeomin, a botulinum toxin type A, and various advanced skincare and neurological treatments. The partnership leverages Biolab's extensive local distribution network and Merz's global expertise in specialized medical therapies.

Therapeutic areas: NeurologyDermatology
Modalities: Small moleculeBiologicProtein
Industry: Biotech

Partnerships

MerzBiolab Farmacêutica

Beyond the preview

Go deeper on Merz Biolab Farma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merz Biolab Farma.

Explore the full profile